Purpose

This study proposes to identify the predisposing/protective modifying genes that underlie the acute attacks in symptomatic patients with Acute Intermittent Porphyria (AIP), an autosomal dominant inborn error of heme biosynthesis.

Condition

Eligibility

Eligible Ages
Over 12 Years
Eligible Sex
All
Accepts Healthy Volunteers
No

Criteria

Inclusion Criteria:

- Willing and able to give informed consent

- 12 years of age or older

- Willingness to provide blood/saliva and urine samples, and clinical information

- A member of an AIP family, defined as (must meet one of the following):

1. proband: possesses an AIP pathogenic mutation and is/has been symptomatic
(experienced acute attacks in the opinion of the investigator)

2. Parents (no known HMBS mutations or heterozygote with familial mutation)

3. First, second, or third degree relative of (a) or (b)

Study Design

Phase
Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Arm Groups

ArmDescriptionAssigned Intervention
Acute Intermittent Porphyria (AIP) Symptomatic patients with Acute Intermittent Porphyria (AIP) A member of an AIP family who possesses an AIP pathogenic mutation and is/has been symptomatic (experienced acute attacks). Parents with no known HMBS mutations or heterozygote with familial mutation or a first, second or third degree relative of the above.

Recruiting Locations

Icahn School of Medicine at Mount Sinai
New York, New York 10029
Contact:
Chloe Cheung
646-369-2045
chloeyihang.cheung@mssm.edu

More Details

Status
Recruiting
Sponsor
Icahn School of Medicine at Mount Sinai

Study Contact

Chloe Cheung
646-369-2045
chloeyihang.cheung@mssm.edu

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.